

Department of Vermont Health Access Pharmacy Benefits Management Program DUR Board Meeting Agenda

June 23, 2020: 6:30 – 8:30 p.m.

•	Executive Session	6:00 - 6:30
•	Introductions and Approval of DUR Board Minutes (Public Comment Prior to Board Action)	6:30 - 6:35
-	DUR Board Chair Election	6:35 - 6:40
•	DVHA Pharmacy Administration Updates	6:40 - 6:45
•	Medical Director Update	6:45 - 6:50
-	Follow-up Items from Previous Meetings Long Term Use of Antibiotics RetroDUR status update Concurrent use of Opioids and Benzodiazepines RetroDUR status	6:50 - 6:55 supdate
-	RetroDUR/ProDUR Introduce: Prescriber PDL Compliance Data presentation: Concurrent Use of Opioids and Antipsychotics	6:55-7:10
•	Clinical Update: Drug Reviews (Public comment prior to Board action)	7:10-7:45
	Riosimilar Drug Reviews	

• None at this time.

Full New Drug Reviews

(Any new drug reviews that also fall within the Therapeutic Class Review (TCR) will be discussed during the Therapeutic Class Review)

- Adakveo® (crizanlizumab-tmca) (Included in the Sickle Cell Disease Agents TCR)
- Amzeeg® (minocycline aerosol, foam)
- Nurtec® ODT (rimegepant)
- Oxbryta® (voxelotor) (Included in the Sickle Cell Disease Agents TCR)
- Reyvow® (lasmiditan)
- Tosymra® (sumatriptan)
- Ubrelvy® (ubrogepant)
- Valtoco® (diazepam spray) (Included in the Anticonvulsants TCR)
- Vyondys® 53 (golodirsen)
- Vyepti® (eptinezumab-jjmr)

•	New Managed Therapeutic Drug Classes	7:45 -7:55
	 Sickle Cell Disease Agents 	
	(Public comment prior to Board action) None at this time	
•	Therapeutic Drug Classes – Periodic Review (Public comment prior to Board action) Anticonvulsants Ophthalmics: Allergic Conjunctivitis Ophthalmics: Antibiotic & Combination Agents Ophthalmics: Anti-Inflammatories Ophthalmics: Dry Eye Agents Ophthalmics: Glaucoma Agents Stimulants and Related Agents	7:55 - 8:30
•	Review of Newly-Developed/Revised Criteria (Public comment prior to Board action) None at this time	8:30 - 8:30
•	General Announcements	8:30 - 8:30
	Adjourn	8:30